About Neocannbio
Neocannbio is a company based in Seoul (South Korea) founded in 2021. Neocannbio has raised $10.9 million across 2 funding rounds from investors including KT&G, Medytox and QUAD Investment Management. Neocannbio operates in a competitive market with competitors including ZYUS Life Sciences, Sanity Group, Terraflos, Avicanna and Little Green Pharma, among others.
- Headquarter Seoul, South Korea
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Neocannbio Co., Ltd.
-
Annual Revenue
$81.82 K (USD)372as on Dec 31, 2022
-
Net Profit
-$209.55 K (USD)-335as on Dec 31, 2022
-
EBITDA
-$209.55 K (USD)-335as on Dec 31, 2022
-
Total Equity Funding
$10.9 M (USD)
in 2 rounds
-
Latest Funding Round
$7.47 M (USD), Series B
Sep 26, 2023
-
Investors
KT&G
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Neocannbio
Neocannbio has successfully raised a total of $10.9M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $7.47 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Neocannbio
Neocannbio has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include KT&G, Medytox and QUAD Investment Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Neocannbio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neocannbio
Investment portfolio details for Neocannbio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Neocannbio
Detailed financials for Neocannbio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neocannbio Comparisons
Peer comparison for Neocannbio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neocannbio
Neocannbio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ZYUS Life Sciences, Sanity Group, Terraflos, Avicanna and Little Green Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cannabis-derived therapeutics for multiple indications are developed.
|
|
| Locked | Locked | Locked |
Developer of cannabinoid-based pharmaceuticals and well-being products
|
|
| Locked | Locked | Locked |
Medical cannabis products are provided based on GMP processes.
|
|
| Locked | Locked | Locked |
Plant-derived cannabinoid products are developed for medical and consumer uses.
|
|
| Locked | Locked | Locked |
Manufacturer of medicinal cannabis for therapeutic use
|
|
| Locked | Locked | Locked |
Developer of medical cannabis products
|
Detailed competitors of Neocannbio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neocannbio
Complete news archive for Neocannbio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neocannbio
Neocannbio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Neocannbio is headquartered in Seoul, South Korea.
Jungyeob Ham is the current CEO of Neocannbio.
Neocannbio is a funded company, having raised a total of $10.9M across 2 funding rounds to date.
Annual revenue of Neocannbio is $81.82K as on Dec 31, 2022.
Neocannbio was founded in 2021 in Seoul, South Korea, within the biotechnology sector focused on cannabinoids. Cannabinoid-based drugs are developed using intelligent delivery systems and synergistic effects to enhance efficacy. A comprehensive cannabinoid library is built from hemp to support efficacy discoveries, assay services, and raw material production. Core technologies encompass microwave processing for high-purity CBD and metabolic engineering for scalable manufacturing.
Neocannbio's top competitors include Avicanna, ZYUS Life Sciences and IMCannabis.
Neocannbio has 9 investors. Key investors include KT&G, Medytox, QUAD Investment Management, Bilanx, and Donghoon Investment.